1. Metabolic Enzyme/Protease
  2. Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producingalpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate(a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as themitochondrion and peroxisome.

Isocitrate Dehydrogenase (IDH) Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-18690
    Enasidenib Inhibitor 99.91%
    Enasidenib is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • HY-18767
    Ivosidenib Inhibitor 99.05%
    Ivosidenib is a inhibitor of IDH1. The detailed information please refer to WO2015127172A1 and WO2015138839A1.
  • HY-18082
    AGI-5198 Inhibitor 99.65%
    AGI-5198 is a novel R132H-IDH1 inhibitor, used for cancer treatment.
  • HY-15734
    AGI-6780 Inhibitor 98.55%
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
  • HY-13972
    Mutant IDH1 inhibitor Inhibitor 98.03%
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
  • HY-100020
    BAY-1436032 Inhibitor 98.94%
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-104042
    Vorasidenib Inhibitor 99.38%
    Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor.
  • HY-104036
    IDH-305 Inhibitor 98.01%
    IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH).
  • HY-18767A
    (R,S)-Ivosidenib Inhibitor 99.40%
    (R,S)-Ivosidenib is a inhibitor of Isocitrate Dehydrogenase (IDH1).
  • HY-19540
    GSK864 Inhibitor 99.36%
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
  • HY-18717
    Mutant IDH1-IN-2 Inhibitor
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
  • HY-12475
    Mutant IDH1-IN-1 Inhibitor
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
  • HY-18690A
    Enasidenib mesylate Inhibitor
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.